Old analysis, but "spot on" ... hold and/or accumulate kids!
Trius Therapeutics’ Tedizolid has Blockbuster Potential for MRSA Infections (TSRX, $5.05)
Posted by Larry Smith on May 30, 2012 • (0)
Trius Therapeutics is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that have increased to epidemic levels in both the hospital and community settings. There are a number of companies competing in this market and a host of new products in development, but I see tedizolid as the most promising of the new products. I am projecting an introduction in the US in 2H, 2014 and see the potential for worldwide sales of $1+ billion in 2020. I estimate that this could lead to a market valuation of three times revenues at that time and a potential stock price of $60+.